测定髓鞘素水平以诊断多发性硬化症。
Determination of medullasin levels for the diagnosis of multiple sclerosis.
作者信息
Aoki Y, Saida T, Nakano I, Saito T, Ikeguchi K, Urabe T, Nishiguchi E, Suzuki H, Takahashi K, Katsuragi H, Mizuno Y
机构信息
Faculty of Human Life Sciences, Jissen Women's University, Tokyo, Japan.
出版信息
Acta Neurol Scand. 2000 Oct;102(4):218-21. doi: 10.1034/j.1600-0404.2000.102004218.x.
OBJECTIVES
To obtain a simple and reliable clinical parameter for the diagnosis of multiple sclerosis among patients with neurological diseases.
PATIENTS AND METHODS
Heparinized peripheral blood was obtained from patients with multiple sclerosis and those with non-inflammatory neurological diseases and healthy volunteers. A new enzyme immunoassay method determining medullasin levels in human granulocytes was developed by using mouse monoclonal antibody against medullasin.
RESULTS
A newly developed enzyme immunoassay method for medullasin can detect as little as 1 ng/ml medullasin and results can be obtained within 2 h. Eighty-five out of 112 patients with multiple sclerosis (75.8%) showed positive results (above means of normals + 2 SD) in the medullasin test, while 15.4% (12/78) of patients with non-inflammatory neurological disease had positive results.
CONCLUSION
This newly developed enzyme immunoassay method for medullasin is considered to be a useful paraclinical test for the diagnosis of multiple sclerosis.
目的
获取一种用于诊断神经疾病患者多发性硬化症的简单可靠的临床参数。
患者与方法
从多发性硬化症患者、非炎性神经疾病患者及健康志愿者中采集肝素化外周血。通过使用抗髓鞘素的小鼠单克隆抗体，开发了一种测定人粒细胞中髓鞘素水平的新型酶免疫测定方法。
结果
新开发的髓鞘素酶免疫测定方法可检测低至1 ng/ml的髓鞘素，且2小时内即可得出结果。112例多发性硬化症患者中有85例（75.8%）在髓鞘素检测中呈阳性结果（高于正常均值+2个标准差），而非炎性神经疾病患者中有15.4%（12/78）呈阳性结果。
结论
新开发的髓鞘素酶免疫测定方法被认为是诊断多发性硬化症的一种有用的临床辅助检查。
Zotero 插件